Gregg Gilbert
Stock Analyst at Truist Securities
(2.29)
# 2,611
Out of 5,173 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $17.77 | -4.33% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $34.74 | +6.52% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $57.00 | +47.37% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $910.55 | -42.34% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $4.68 | +177.78% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $11.82 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $115.68 | -19.61% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $22.29 | +115.34% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.64 | +1,485.37% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.64 | +23,337.50% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $9.57 | +715.05% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $115.23 | -32.31% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $28.77 | -37.43% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $200.36 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $182.32 | -4.01% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $204.93 | -67.79% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $17.77
Upside: -4.33%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $34.74
Upside: +6.52%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $57.00
Upside: +47.37%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $910.55
Upside: -42.34%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $4.68
Upside: +177.78%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $11.82
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $115.68
Upside: -19.61%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $22.29
Upside: +115.34%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.64
Upside: +1,485.37%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.64
Upside: +23,337.50%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $9.57
Upside: +715.05%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $115.23
Upside: -32.31%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $28.77
Upside: -37.43%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $200.36
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $182.32
Upside: -4.01%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $204.93
Upside: -67.79%